human coagulation factor viii

It is used for the treatment and prevention of bleeding in patients with hemophilia A (factor VIII deficiency) and for the treatment of acquired deficiency of this factor. It is also indicated for hemophilia A patients who have developed antibodies against factor VIII and for the prophylaxis or treatment of bleeding in von Willebrand disease, when treatment with desmopressin is ineffective or contraindicated.

Form: solution for infusion, powder and solvent for preparation

ATC: B02BD06

Manufacturer: GRIFOLS ITALIA S.P.A.

This medicinal product is used to prevent and treat bleeding caused by congenital factor VIII deficiency (haemophilia A) or von Willebrand disease.

Form: solution for injection, powder and solvent

ATC: B02BD06

Manufacturer: CSL BEHRING GMBH

It is used for the treatment or prevention of bleeding in patients with hemophilia A (a congenital deficiency of factor VIII). The drug replaces the lack or malfunction of this protein, helping the blood to clot.

Form: solution for injection, powder and solvent

ATC: B02BD02

Manufacturer: NOVO NORDISK A/S

It is used for the treatment and prevention of bleeding in patients with hemophilia A, a condition caused by an inherited deficiency of coagulation factor VIII.

Form: solution for injection, powder and solvent

ATC: B02BD06

Manufacturer: OCTAPHARMA ITALY S.P.A.

It is used for the treatment and prevention of bleeding in patients with hemophilia A (factor VIII deficiency) or with von Willebrand disease with factor VIII deficiency.

Form: solution for injection, powder and solvent

ATC: B02BD06

Manufacturer: BAXALTA INNOVATIONS GMBH